Neurosense Therapeutics is trading at $0.50 (5% up) as investors engage in bargain-hunting following a series of sharp declines over the past week.
- The rebound is driven by interest in oversold names after a period of company-specific selling pressure.
- The stock's recovery comes despite broader weakness across the biotech sector, which has weighed on industry peers.
- Traders appear to be capitalizing on the recent selloff to establish positions at lower valuation levels.